Top Markets
#1 Black Phoenix Black Phoenix +21,646.82%
#2 Nesa Nesa +764.54%
#3 Kinesis Silver Kinesis Silver +54.95%
#4 QuantixAI QuantixAI +23.71%
#5 BNB Attestation Service BNB Attestation Service +23.53%
#6 EXOD EXOD +22.78%
#7 Cash Cat Cash Cat +21.46%
#8 Derive Derive +18.76%
#9 Pons Pons +18.29%
#10 Alchemist AI Alchemist AI +16.40%
Coin of the day
Black Phoenix Black Phoenix
設定
言語
日本
通貨
USD
テーマ
Cypherpunk Technologies Inc. Cypherpunk Technologies Inc.

Cypherpunk Technologies Inc.

CYPH
株式のランク #19166
Cypherpunk Technologies Inc. is a biopharmaceutical company dedicated to the... Cypherpunk Technologies Inc. is a biopharmaceutical company dedicated to the acquisition and development of antibody treatments for cancer. The firm's flagship investigational drug, DKN-01, is a monoclonal antibody designed to suppress Dickkopf-related protein 1 and is currently progressing through multiple clinical trials for various esophagogastric, gynecologic, and colorectal cancers. Additionally, the company is advancing FL-501, another monoclonal antibody that targets the GDF-15 protein, which is presently in preclinical development. Cypherpunk has established an agreement with Adimab, LLC and BeiGene, Ltd., granting it options and licenses to advance and market DKN-01 across Asia (excluding Japan), Australia, and New Zealand. Founded in 2011, the company operates from Cambridge, Massachusetts, and was formerly known as Leap Therapeutics, Inc. until its renaming in November 2025.
株価
$1.62
最終同期: 2026-08-25
時価総額
$172.47M
変化（1日）
-3.57%
変化（1年）
446.74%
国
US
取引 Cypherpunk Technologies Inc. (CYPH)

カテゴリー

Healthcare
Cypherpunk Technologies Inc.（CYPH）の収益
Aug 2026 時点の収益 TTM: 0
Cypherpunk Technologies Inc. の最新の財務報告によると、現在の収益 (TTM) は 0 です。2026 年には 0 の収益があり、これは 2026 年の 0 と比較して 同等 です。収益とは、企業が商品やサービスの販売によって得る総所得です。利益とは異なり、費用は差し引かれません。
Cypherpunk Technologies Inc. の収益履歴（2026 ～ 2026）
各年末の収益
年 収益 変化
提供された日付のデータは十分ではありません。
同業他社の収益
企業 収益 収益の差 国
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH